Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Yuhan Corporation
Although South Korean pharma firms are largely sailing toward the common goal of globalization, they have different strategies to reach their goals. Scrip takes a look at the variety of paths being pursued.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
Although there weren’t many large-scale partnerships as in previous years, Korean biopharma firms were involved in a broad range of deals across diverse therapeutic areas in 2020, with ADCs, oncology and domestic alliances emerging as key trends.
Another victim of the COVID-pandemic, Celgene's $9-per-share contingent value right tied to BMS obtaining approval of three drugs goes unrealized due to FDA travel restrictions slowing down site inspections. Clene goes public, United Therapeutics buys PRV from Y-mAbs.
- Generic Drugs
- Drug Discovery Tools
- Other Names / Subsidiaries
- Yuhan USA